Your browser is no longer supported. Please, upgrade your browser.
Iterum Therapeutics plc
Index- P/E- EPS (ttm)-4.08 Insider Own0.40% Shs Outstand49.08M Perf Week21.54%
Market Cap79.58M Forward P/E- EPS next Y-1.08 Insider Trans-21.79% Shs Float42.24M Perf Month51.92%
Income-64.50M PEG- EPS next Q-0.19 Inst Own34.20% Short Float13.90% Perf Quarter200.78%
Sales0.00M P/S- EPS this Y-32.40% Inst Trans151.87% Short Ratio0.68 Perf Half Y38.60%
Book/sh-2.74 P/B- EPS next Y56.30% ROA-204.60% Target Price1.75 Perf Year-40.82%
Cash/sh0.20 P/C8.04 EPS next 5Y- ROE149.30% 52W Range0.45 - 6.02 Perf YTD59.76%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-73.75% Beta-
Dividend %- Quick Ratio0.30 Sales past 5Y- Gross Margin- 52W Low250.33% ATR0.20
Employees44 Current Ratio0.30 Sales Q/Q- Oper. Margin- RSI (14)62.91 Volatility24.70% 13.23%
OptionableNo Debt/Eq- EPS Q/Q72.10% Profit Margin- Rel Volume3.44 Prev Close1.81
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume8.69M Price1.58
Recom3.20 SMA2026.72% SMA5065.62% SMA20013.86% Volume29,055,460 Change-12.71%
Jun-02-20Downgrade RBC Capital Mkts Outperform → Sector Perform $7 → $2
Jan-21-20Downgrade Gabelli & Co Buy → Sell
Dec-11-19Downgrade SVB Leerink Outperform → Mkt Perform
Jun-21-19Initiated H.C. Wainwright Buy $17
Jan-25-21 07:00AM  
Jan-06-21 05:00PM  
Dec-23-20 07:00AM  
Dec-21-20 05:00PM  
Dec-07-20 08:00AM  
Nov-30-20 09:15AM  
Nov-16-20 06:45AM  
Oct-23-20 12:02AM  
Oct-19-20 07:10PM  
Oct-01-20 05:15PM  
Sep-30-20 07:45AM  
Sep-08-20 04:30PM  
Sep-02-20 07:00AM  
Aug-31-20 08:00PM  
Aug-11-20 08:00AM  
Aug-06-20 06:45AM  
Jul-13-20 04:05PM  
Jun-30-20 09:12AM  
Jun-29-20 07:30AM  
Jun-15-20 04:30PM  
Jun-03-20 03:45PM  
Jun-02-20 09:42AM  
Jun-01-20 08:30AM  
May-14-20 09:31AM  
Apr-09-20 04:05PM  
Mar-31-20 07:00AM  
Mar-12-20 06:45AM  
Feb-19-20 07:30AM  
Jan-17-20 06:15AM  
Jan-03-20 03:15PM  
Dec-26-19 05:00PM  
Dec-12-19 09:42AM  
Dec-11-19 07:21AM  
Dec-10-19 04:10PM  
Nov-30-19 10:18AM  
Nov-18-19 07:30AM  
Nov-12-19 07:05PM  
Nov-08-19 01:01PM  
Nov-06-19 10:30AM  
Oct-01-19 10:07AM  
Sep-27-19 04:30PM  
Sep-09-19 03:24PM  
Aug-14-19 08:15AM  
Aug-06-19 10:30AM  
Aug-01-19 07:30AM  
Jul-10-19 12:13PM  
Jul-01-19 09:13AM  
Jun-21-19 07:30AM  
Jun-20-19 11:13AM  
Jun-07-19 09:27AM  
May-14-19 07:00AM  
Apr-12-19 10:08AM  
Apr-11-19 07:30AM  
Mar-28-19 09:00AM  
Mar-25-19 07:00AM  
Mar-19-19 07:00AM  
Feb-21-19 10:15AM  
Feb-19-19 07:30AM  
Jan-17-19 10:00AM  
Dec-20-18 12:36PM  
Nov-14-18 07:15AM  
Nov-05-18 04:05PM  
Oct-05-18 08:00AM  
Sep-25-18 04:05PM  
Sep-20-18 08:00AM  
Sep-18-18 08:00AM  
Aug-14-18 07:30AM  
Aug-09-18 04:05PM  
Jun-06-18 10:08AM  
May-25-18 12:51AM  
May-24-18 08:15PM  
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Matthews Judith M.Chief Financial OfficerSep 30Sale1.6456,13092,0530Oct 02 09:00 PM
Sofinnova Venture Partners IX,10% OwnerJun 02Sale1.61400,000642,9601,226,514Jun 03 08:20 PM
Sofinnova Venture Partners IX,10% OwnerJun 01Sale1.69100,000169,1201,626,514Jun 03 08:20 PM